Thriving on challenge: NICE’s dementia guidelines

‘NICE is an organization with very significant resources at its disposal ... It is able to set the agenda for the development of new treatments as well as to evaluate their cost–effectiveness.’ Steve Iliffe University College London, London, UK; Associate Director, DeNDRoN National Co-ordinating Centre, UK Tel.: +44 207 83

[1]  K. Chalkidou,et al.  Making a decision to wait for more evidence: when the National Institute for Health and Clinical Excellence recommends a technology only in the context of research , 2007, Journal of the Royal Society of Medicine.

[2]  M. Quigley.  A NICE fallacy , 2007, Journal of Medical Ethics.

[3]  P. Littlejohns,et al.  Reallocating resources: how should the National Institute for Health and Clinical Excellence guide disinvestment efforts in the National Health Service? , 2007, Journal of health services research & policy.

[4]  S. Bryan,et al.  How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach , 2007, Journal of health services research & policy.

[5]  Stirling Bryan,et al.  Seeing the NICE side of cost-effectiveness analysis: a qualitative investigation of the use of CEA in NICE technology appraisals. , 2007, Health economics.

[6]  T. Milewa.  Health technology adoption and the politics of governance in the UK. , 2006, Social science & medicine.

[7]  James Raftery,et al.  Commentary: A clinical challenge , 2006, BMJ : British Medical Journal.

[8]  J. Michaels.  Improving NICE's social value judgments , 2006, BMJ : British Medical Journal.

[9]  G. Livingston,et al.  Drug treatment for Alzheimer's disease: the way forward , 2006, International journal of geriatric psychiatry.

[10]  L. Schneider.  The post‐modern world of Alzheimer's disease trials: how much is an ADAS‐cog point worth in central London? , 2006, International journal of geriatric psychiatry.

[11]  P. Herrling,et al.  List of Drugs in Development for Neurodegenerative Diseases , 2005, Neurodegenerative Diseases.

[12]  Steven D Pearson,et al.  Quality, innovation, and value for money: NICE and the British National Health Service. , 2005, JAMA.

[13]  P. Herrling,et al.  List of Drugs in Development for Neurodegenerative Diseases , 2004, Neurodegenerative Diseases.

[14]  N. Devlin,et al.  Patients' views of explicit rationing: what are the implications for health service decision-making? , 2003, Journal of health services research & policy.

[15]  Peter Littlejohns,et al.  Views of Directors of Public Health about NICE Appraisal Guidance: results of a postal survey. National Institute for Clinical Excellence. , 2002, Journal of public health medicine.

[16]  M. Rawlins.  In pursuit of quality: the National Institute for Clinical Excellence , 1999, The Lancet.

[17]  Mark Sculpher,et al.  The role of NICE technology appraisal in NHS rationing. , 2007, British medical bulletin.

[18]  S. Iliffe.  The National Institute for Health and Clinical Excellence (NICE) and Drug Treatment for Alzheimer’s Disease , 2007, CNS drugs.